AUA 2020: Multicenter Comparison of Outcomes for Clinical and Pathologic T3a Renal Cell Carcinoma

(UroToday.com) The TNM grading system for renal cell carcinoma (RCC) has been established and widely used for many years. In it, T3 is defined by a tumor that extends into major veins or perinephric tissues but not into the ipsilateral adrenal gland and not beyond the Gerota fascia. This is subdivided into T3a which is characterized by the tumor which invades perirenal and/or renal sinus fat but not beyond the Gerota fascia or tumor which grossly extends into the renal vein or its segmental (muscle-containing) branches while T3b and T3c are characterized by more extensive thrombus. In the case of T3a, while the invasion of perirenal or sinus fat has been shown to have important prognostic information, it may be difficult to identify on pre-operative imaging. As a result, patients with clinical T2 kidney cancers may be upstaged to pT3a following surgical extirpation. In a podium presentation at the American Urologic Association Virtual Annual Meeting, Aaron Bradshaw and colleagues presented results of a multicenter cohort study examining the survival outcomes of patients with clinical T3a compared to those who were upstaged to pT3a.

The authors undertook a retrospective, multicenter cohort study of patients with RCC with clinical or pathological stage T3a who were treated with surgical excision. The primary outcome of interest was recurrence-free survival (RFS) while secondary outcomes were overall survival (OS) and cancer-specific survival (CSS). The authors considered clinical T3a vs pathologically upstaged T3a as the exposure of interest. Kaplan-Meier analyses (KMA) were conducted to describe RFS, OS, and CSS with a log-rank test comparing survival between these two groups. Cox proportional hazard modeling was utilized for multivariable analysis of the primary outcome.

Dr. Bradshaw identified a total of 1314 patients eligible patients of whom 309 had clinical T3a while 1005 were pathologically upstaged to T3a. Patients with pathologically upstaged pT3a were more likely to be female (p=0.02) and have a higher BMI (p<0.01).

The average tumor size was similar between groups (cT3a 7.7 vs. pT3a 7.2 cm, p=0.26), however, a higher proportion of cT3a underwent radical nephrectomy (90.9% vs. 56.7%, p<0.01), likely reflecting more difficult surgical anatomy. However, positive surgical margins were more common among pT3a patients (9.6% vs 2.3% cT3a, p<0.01), potentially as a result of the increased utilization of partial nephrectomy, with a similar proportion having pathologically positive nodes (11.5% pT3a vs. 11.7% cT3a, p=0.96).
RecurrenceFreeSurvival_PD11-5.png

Kaplan Meier analysis demonstrated 5-year RFS of 52.2% and 55.6% for cT3a and pT3a respectively (p=0.04). However, there were no significant differences in overall survival at 5-years (69.0% vs 59.0%, p=0.20) or cancer-specific survival (76.7% vs 72.6%, p=0.70) between those with clinical T3a and pathologically upstaged disease.

On multivariable Cox proportional hazard modeling, cT3a vs. pT3a staging was not an independent risk factor for recurrence-free survival (p=0.08). Increasing age (HR 1.01, p=0.03), clear cell RCC (HR 1.32, p=0.03), and positive node status (HR 3.83, p<0.01) were independent risk factors of recurrence while sex (p=0.13), positive surgical margins (p=0.30), and type of surgery (p=0.95) were not significant.

Using this large, multi-institutional dataset, Bradshaw and colleagues demonstrated that, for patients with T3a kidney cancer, the clinically identified extra-renal invasion was not prognostically different than the pathologically upstaged disease.

Presented by: Aaron Bradshaw, BS, University of California, San Diego School of Medicine, San Diego, CA 

Written by: Christopher J.D. Wallis, Urologic Oncology Fellow, Vanderbilt University Medical Center, Nashville, TN, USA, Twitter: @WallisCJD, at the 2020 American Urological Association (AUA) Annual Meeting, Virtual Experience #AUA20, June 27- 28, 2020

email news signup